Moonwalk Biosciences secured a funding round led by Eli Lilly to advance its adipose tissue-directed siRNA therapy into first-in-human studies for obesity in late 2027.
Public source
Publisher name
Public post
Weight-loss giant Eli Lilly joined Moonwalk Biosciences' latest funding round, which will be used to advance the biotech's adipose tissue–directed siRNA therapy into fir…
Company
Moonwalk Biosciences
Pioneering novel therapeutics in adipose biology and tissue, driven by deep genetic and epigenetic insights
- Industry
- Biotechnology Research
- Location
- South San Francisco, US
- Company size
- 11–50 employees
About Moonwalk Biosciences
Moonwalk Biosciences is pioneering novel therapeutics in adipose biology and tissue, driven by deep genetic and epigenetic evidence and insights. It utilizes its discovery platform to identify novel targets involved in obesity and cardiometabolic disease, and is advancing an early stage pipeline of therapeutic candidates.
See moreLatest activity
Latest activity from Moonwalk Biosciences
11 signals
Products & Services
Moonwalk Biosciences advanced its adipose-targeted RNAi medicines for obesity and cardiometabolic diseases and its lead program MW101 toward the clinic.
Capital & Finance
Moonwalk Biosciences received $70 million Series B financing from the NYSE.
Research & Knowledge
Moonwalk Biosciences designed programs to selectively deliver siRNA therapeutics directly to adipose tissue to modulate novel non-incretin pathways underlying obesity.
Discover more
Similar signals
Similar public activity from other companies.
Capital & Finance
bioSeedin
bioSeedin closed an oversubscribed $70 million Series B financing for Moonwalk Biosciences to advance RNAi therapies for obesity and cardiometabolic diseases.
Capital & Finance
Cloverleaf Bio
Cloverleaf Bio closed a $33 Million seed round led by 4BIO Capital to advance a novel class of tRNA-based therapeutics for cancer.
Capital & Finance
Alpha Wave Global
Alpha Wave Global co-led Moonwalk Biosciences' $70M Series B proceeds will support the advancement of MW101 into first-in-human clinical studies and accelerate development of a pipeline of adipose-selective RNAi medicines targeting novel biology.
Capital & Finance
BiotechTV
BiotechTV reports that Bay Area based Moonwalk Biosciences announced a $70M series B funding round.
Capital & Finance
Gossamer Bio